[1] 郑荣寿,张思维,孙可欣,等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2023,45(3):212-220. DOI:10.3760/cma.j.cn112152-20220922-00647.
[2] Schizas D, Charalampakis N, Kole C,et al. Immunotherapy for esophageal cancer: a 2019 update[J]. Immunotherapy,2020,12(3):203-218.DOI: 10.2217/imt-2019-0153.
[3] He Y, Liang D, Du L,et al. Clinical characteristics and survival of 5283 esophageal cancer patients: a multicenter study from eighteen hospitals across six regions in China[J]. Cancer Commun (Lond),2020,40(10):531-544.DOI: 10.1002/cac2.12087.
[4] 袁晓莉,王振波. 食管鳞癌的肿瘤免疫微环境和免疫检查点抑制剂研究进展[J]. 国际医药卫生导报,2023,29(3):310-314. DOI:10.3760/cma.j.issn.1007-1245. 2023.03.004.
[5] Kato K, Shah MA, Enzinger P,et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol,2019 ,15(10):1057-1066.DOI: 10.2217/fon-2018-0609.
[6] 薛丽燕,李印,黄镜,等. 中国食管癌PD-L1蛋白表达检测临床病理专家共识[J]. 中华肿瘤杂志,2023,45(4):291-297. DOI:10.3760/cma.j.cn112152-20221129-00792.
[7] Palmer CS, Ostrowski M, Balderson B,et al. Glucose metabolism regulates T cell activation, differentiation, and functions[J]. Front Immunol,2015,6:1.DOI: 10.3389/fimmu.2015.00001.
[8] Zhao L, Zhuang Y, Fu K,et al. Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma[J]. Eur J Nucl Med Mol Imaging,2020,47(5):1065-1074. DOI: 10.1007/s00259-019-04654-4.
[9] Seol HY, Kim YS, Kim SJ. Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis[J]. Clin Radiol,2021 ,76(11):863.e19-863.e25.DOI: 10.1016/j.crad.2021.06.012.
[10] Li J, Chen R, Chen Y,et al. Relationship between the expression of PD-L1 and 18F-FDG uptake in pancreatic ductal adenocarcinoma[J]. Br J Cancer,2023,129(3):541-550.DOI: 10.1038/s41416-023-02297-9.
[11] Wu X, Huang Y, Zhao Q,et al. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer[J]. EJNMMI Res,2020 ,10(1):51.DOI: 10.1186/s13550-020-00639-9.
[12] Chen R, Chen Y, Huang G,et al. Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer[J]. Aging (Albany NY),2019 ,11(24):12270-12277.DOI: 10.18632/aging.102567.
[13] Li J, Ge S, Sang S,et al. Evaluation of PD-L1 expression level in patients with non-small cell lung cancer by 18F-FDG PET/CT radiomics and clinicopathological characteristics[J]. Front Oncol ,2021,11:789014.DOI: 10.3389/fonc.2021.789014.
[14] Kuriyama K, Higuchi T, Yokobori T,et al. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma[J]. Cancer Sci,2020,111(6):1969-1978. DOI: 10.1111/cas.14421.
[15] 方文涛. 通过食管癌TNM新分期(第八版)解读2017年NCCN食管鳞癌诊疗指南[J]. 中华胃肠外科杂志,2017,20(10):1122-1126. DOI:10.3760/cma.j.issn.1671- 0274 .2017.10.008.
[16] Yagi T, Baba Y, Ishimoto T,et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer[J]. Ann Surg,2019 ,269(3):471-478.DOI: 10.1097/SLA.0000000000002616.
[17] Rong L, Liu Y, Hui Z,et al. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population[J]. Diagn Pathol,2019,14(1):6.DOI: 10.1186/s13000-019-0778-4.
[18] 余琦瑶,李斌,冯海明,等. PD-1/PD-L1在食管鳞状细胞癌中的表达及其与肿瘤预后相关性的系统评价与Meta分析[J]. 中国胸心血管外科临床杂志,2021,28(11):1352-1359. DOI:10.7507/1007-4848.202008021.
[19] 徐小玉,吴兵,韩海娥. 食管癌组织PD-1及PD-L1表达对中晚期食管癌患者化疗近期疗效的影响[J]. 国际医药卫生导报,2020,26(3):370-373. DOI:10.3760/cma.j.issn.1007-1245.2020.03.024.
[20] Zhao L, Liu J, Wang H,et al. Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens[J]. Br J Radiol,2021,94(1119):20200397.DOI: 10.1259/bjr.20200397.
[21] Lim SH, Hong M, Ahn S,et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer[J]. Eur J Cancer,2016,52:1-9.DOI: 10.1016/j.ejca.2015.09.019.
[22] Cui H, Li Y, Li S,et al. Prognostic function of programmed cell death-ligand 1 in esophageal squamous cell carcinoma patients without preoperative therapy: a systematic review and meta-analysis[J]. Front Oncol,2021,11:693886.DOI: 10.3389/fonc.2021.693886.
[23] Zhou X, Hu Y, Sun H,et al. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging,2023,50(10):3107-3115.DOI: 10.1007/s00259-023-06251-y.
[24] Monsrud AL, Avadhani V, Mosunjac MB,et al. Programmed death ligand-1 (PD-L1) expression in cervical squamous cell carcinoma: does it correlate with outcomes?[J].Int J Gynecol Pathol,2023,42(6):535-543.DOI: 10.1097/PGP.0000000000000975.
[25] 中华医学会核医学分会PET学组. 免疫检查点抑制剂治疗恶性肿瘤的PET/CT评价专家共识(2020版)[J]. 中华肿瘤杂志,2020,42(9):697-705. DOI:10.3760/cma.j.cn112152- 20200623-00590.
[26] 石鑫磊,葛小林,狄晓珂,等. PET/CT在食管癌肿瘤区勾画中的应用[J]. 中国CT和MRI杂志,2023,21(7):77-79. DOI:10.3969/j.issn.1672-5131.2023.07.026.
[27] 吴宇诗,冯彦林. 18F-FDG PET/CT在肿瘤PD-1/PD-L1免疫治疗中的研究进展 [J]. 国际放射医学核医学杂志,2021,45(2):94-98. DOI:10.3760/cma.j.cn121381-201912024- 00016.
[28] Lin J, Fang W, Xiang Z,et al. Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion[J]. Front Immunol,2023,14:1189953.DOI: 10.3389/fimmu.2023.1189953.
[29] Song S, Zhang Y, Duan X,et al. HIF-1α/IL-8 axis in hypoxic macrophages promotes esophageal cancer progression by enhancing PD-L1 expression[J]. Cancer Gene Ther,2023,30(2):358-367.DOI: 10.1038/s41417-022-00551-5.
[30] Wen Q, Yang Z, Zhu J,et al. Pretreatment CT-based radiomics signature as a potential imaging biomarker for predicting the expression of PD-L1 and CD8+TILs in ESCC[J]. Onco Targets Ther,2020,13:12003-12013.DOI: 10.2147/OTT.S261068.
|